This whole thing seems backward from what
I had hoped to see out of my little biotech
companies. Sibia should have waited for 1508Y
or 1553A data, found a partner, then gone on
to begin work on other candidates on their own.
(Easy for me to say, I'm just a shareholder)
Am I missing something? --What is the point of
establishing a portfolio of these, just to see
your leverage undone when these companies again
and again whore themselves out? Well, I suppose
it has got to the point where it is about job
security now, nobody wants the stock, and these
folks have to think about protecting themselves--
and maybe the two in phase II are not looking so
promising, so they threw the option in just to do
the deal.
So...LLY has an option to become a partner
for the two in phase II, what a deal, no risk
for LLY. Unfortunately less reward for SIBI--great
data, okay, we will be happy to take that off your
hands. But mainly just confusion for shareholders
(well, maybe you fellas get it, but I sure don't!--
no wonder it is so difficult to attract folks to
this sector).
I should think Sibia just fell of the munch list,
and maybe that is why the stock did not close up
much today. Less risk, but less reward--boring,
I could have filled my account with other things
if this is the way it is going to go.
|
